Citadel Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $165M | Sell |
213,700
-51,600
| -19% | -$39.5M | 0.03% | 540 |
|
|
2025
Q4 | $205M | Buy |
265,300
+56,400
| +27% | +$38.3M | 0.03% | 475 |
|
|
2025
Q3 | $117M | Sell |
208,900
-81,600
| -28% | -$46.1M | 0.02% | 729 |
|
|
2025
Q2 | $153M | Buy |
290,500
+62,500
| +27% | +$34.9M | 0.03% | 516 |
|
|
2025
Q1 | $145M | Buy |
228,000
+59,400
| +35% | +$40.9M | 0.03% | 499 |
|
|
2024
Q4 | $120M | Buy |
168,600
+23,200
| +16% | +$19.5M | 0.02% | 641 |
|
|
2024
Q3 | $153M | Buy |
145,400
+61,900
| +74% | +$68.9M | 0.03% | 482 |
|
|
2024
Q2 | $87.8M | Sell |
83,500
-39,400
| -32% | -$38.2M | 0.02% | 760 |
|
|
2024
Q1 | $118M | Sell |
122,900
-118,500
| -49% | -$113M | 0.02% | 608 |
|
|
2023
Q4 | $212M | Sell |
241,400
-17,100
| -7% | -$14.1M | 0.04% | 331 |
|
|
2023
Q3 | $213M | Sell |
258,500
-42,900
| -14% | -$33.7M | 0.05% | 298 |
|
|
2023
Q2 | $217M | Sell |
301,400
-154,600
| -34% | -$119M | 0.04% | 298 |
|
|
2023
Q1 | $375M | Buy |
456,000
+74,200
| +19% | +$56M | 0.08% | 142 |
|
|
2022
Q4 | $275M | Sell |
381,800
-91,800
| -19% | -$67.7M | 0.06% | 228 |
|
|
2022
Q3 | $326M | Buy |
473,600
+202,400
| +75% | +$127M | 0.07% | 171 |
|
|
2022
Q2 | $160M | Buy |
271,200
+87,700
| +48% | +$57M | 0.04% | 365 |
|
|
2022
Q1 | $128M | Sell |
183,500
-126,500
| -41% | -$80M | 0.03% | 541 |
|
|
2021
Q4 | $196M | Buy |
310,000
+9,000
| +3% | +$5.53M | 0.04% | 356 |
|
|
2021
Q3 | $182M | Buy |
301,000
+19,100
| +7% | +$11.9M | 0.04% | 384 |
|
|
2021
Q2 | $157M | Sell |
281,900
-79,900
| -22% | -$40.5M | 0.04% | 430 |
|
|
2021
Q1 | $171M | Sell |
361,800
-140,800
| -28% | -$68.6M | 0.04% | 345 |
|
|
2020
Q4 | $243M | Buy |
502,600
+51,600
| +11% | +$27.9M | 0.06% | 196 |
|
|
2020
Q3 | $252M | Buy |
451,000
+106,500
| +31% | +$64.6M | 0.07% | 144 |
|
|
2020
Q2 | $215M | Sell |
344,500
-36,000
| -9% | -$20.4M | 0.08% | 163 |
|
|
2020
Q1 | $186M | Sell |
380,500
-157,000
| -29% | -$64.8M | 0.08% | 153 |
|
|
2019
Q4 | $202M | Buy |
537,500
+138,300
| +35% | +$46.5M | 0.09% | 166 |
|
|
2019
Q3 | $111M | Buy |
399,200
+86,800
| +28% | +$25.7M | 0.05% | 356 |
|
|
2019
Q2 | $97.8M | Sell |
312,400
-22,800
| -7% | -$7.59M | 0.04% | 406 |
|
|
2019
Q1 | $138M | Sell |
335,200
-23,700
| -7% | -$9.76M | 0.07% | 250 |
|
|
2018
Q4 | $134M | Buy |
358,900
+33,100
| +10% | +$12.1M | 0.07% | 233 |
|
|
2018
Q3 | $132M | Buy |
325,800
+25,200
| +8% | +$9.59M | 0.06% | 315 |
|
|
2018
Q2 | $104M | Buy |
300,600
+75,900
| +34% | +$23.7M | 0.05% | 357 |
|
|
2018
Q1 | $77.4M | Sell |
224,700
-49,500
| -18% | -$17.2M | 0.04% | 408 |
|
|
2017
Q4 | $103M | Buy |
274,200
+3,400
| +1% | +$1.38M | 0.06% | 320 |
|
|
2017
Q3 | $121M | Buy |
270,800
+19,900
| +8% | +$9.47M | 0.09% | 198 |
|
|
2017
Q2 | $123M | Buy |
250,900
+79,200
| +46% | +$34.7M | 0.1% | 173 |
|
|
2017
Q1 | $66.5M | Sell |
171,700
-18,700
| -10% | -$6.93M | 0.06% | 327 |
|
|
2016
Q4 | $69.9M | Buy |
190,400
+5,400
| +3% | +$2.05M | 0.07% | 269 |
|
|
2016
Q3 | $74.4M | Sell |
185,000
-32,800
| -15% | -$13.2M | 0.07% | 230 |
|
|
2016
Q2 | $76.1M | Buy |
217,800
+23,100
| +12% | +$8.9M | 0.08% | 206 |
|
|
2016
Q1 | $70.2M | Sell |
194,700
-53,100
| -21% | -$21.9M | 0.09% | 198 |
|
|
2015
Q4 | $135M | Sell |
247,800
-33,900
| -12% | -$18.4M | 0.15% | 130 |
|
|
2015
Q3 | $131M | Buy |
281,700
+95,900
| +52% | +$51.5M | 0.12% | 148 |
|
|
2015
Q2 | $94.8M | Sell |
185,800
-8,200
| -4% | -$4M | 0.08% | 253 |
|
|
2015
Q1 | $87.6M | Buy |
194,000
+46,600
| +32% | +$19.7M | 0.08% | 264 |
|
|
2014
Q4 | $60.5M | Buy |
147,400
+26,500
| +22% | +$10.4M | 0.06% | 369 |
|
|
2014
Q3 | $43.6M | Buy |
120,900
+26,500
| +28% | +$8.88M | 0.05% | 481 |
|
|
2014
Q2 | $26.7M | Sell |
94,400
-32,400
| -26% | -$9.6M | 0.03% | 655 |
|
|
2014
Q1 | $38.1M | Sell |
126,800
-21,800
| -15% | -$6.72M | 0.04% | 510 |
|
|
2013
Q4 | $40.9M | Sell |
148,600
-33,000
| -18% | -$9.49M | 0.05% | 437 |
|
|
2013
Q3 | $56.8M | Buy |
181,600
+63,600
| +54% | +$16.7M | 0.09% | 261 |
|
|
2013
Q2 | $26.5M | Buy |
+118,000
| New | +$27.5M | 0.05% | 501 |
|
Other funds holding REGN
VCM
N
Citadel Advisors's REGN Position: Q1 2026 in Review
Citadel Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, selling an estimated $74.5M and leaving 47,687 shares worth $36.8M. The position accounts for 0.01% of the portfolio, ranked #1652.
Citadel Advisors first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $357M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Citadel Advisors held 47,687 shares of Regeneron Pharmaceuticals worth $36.8M as of Q1 2026.
- Citadel Advisors sold 97,283 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $74.5M.
- Regeneron Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1652 holding.
- Citadel Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's Regeneron Pharmaceuticals position peaked at $357M in Q2 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.